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Abstract
The forkhead box O3 (FOXO3, or FKHRL1) protein is a member of the FOXO
subclass of transcription factors. FOXO proteins were originally identified as
regulators of insulin-related genes; however, they are now established
regulators of genes involved in vital biological processes, including substrate
metabolism, protein turnover, cell survival, and cell death.   is one of theFOXO3
rare genes that have been consistently linked to longevity in   models.in vivo
This review provides an update of the most recent research pertaining to the
role of FOXO3 in (i) the regulation of protein turnover in skeletal muscle, the
largest protein pool of the body, and (ii) the genetic basis of longevity. Finally, it
examines (iii) the role of microRNAs in the regulation of FOXO3 and its impact
on the regulation of the cell cycle.
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Introduction
The forkhead box O3 (FOXO3, or FKHRL1) protein is one of 
about 40 forkhead box (FOX) transcription factors encoded by 
the mammalian genome1. FOX transcription factors are versatile 
proteins containing an evolutionarily conserved winged helix 
DNA-binding motif of about 100 residues at the N-terminal 
region, the forkhead (FKH) domain2–4. FOXO3 belongs to 
the FOXO subclass (made of FOXO1, FOXO3, FOXO4, 
and FOXO6), which historically is known to regulate insulin 
signaling (comprehensively reviewed in 5,6). Numerous regulatory 
processes, including phosphorylation, acetylation, ubiquitination, 
methylation7,8, and microRNA (miRNA) binding9, can modulate 
FOXO3 transcriptional activity. Of particular interest for human 
health, FOXO3 is under the control of the phosphatidylinositol 
3-kinase (PI3K)/Akt signaling pathway10. In its non- 
phosphorylated form, FOXO3 localizes at the nucleus where 
it regulates gene transcription. Activation of the PI3K/Akt 
pathway results in the phosphorylation of FOXO3 at three 
conserved residues11. This usually causes its exclusion from 
the nucleus and stops the transcriptional activation of its tar-
get genes1,12. Phosphorylated FOXO3 therefore represents the 
inactive form of the protein. Through PI3K/Akt, FOXO3 mediates 
biologicalprocesses that are essential for health over the lifespan, 
including substrate metabolism, protein turnover, cell survival, 
and cell death11,13,14.
Our research group investigates skeletal muscle wasting and 
miRNA-mediated regulation. Although the involvement of 
FOXO3 in these processes is undeniable, these two topics have 
not been reviewed in the specific context of FOXO3. In addi-
tion, the role and regulation of FOXO3 in the genetics of 
longevity constitute a very dynamic research field, justifying the 
need for an updated review encompassing the research articles 
published over the last 3 years.
FOXO3 and the regulation of skeletal muscle 
homeostasis
FOXO proteins are expressed across multiple tissues of the 
body but their expression level, function, and targets are tissue 
specific. In mice, Foxo3 mRNA is enriched in the heart, brain, 
spleen, and kidney and, to a certain extent, skeletal muscle15. 
FOXO3 is a key player in the control of skeletal muscle protein 
turnover and a central effector of PI3K/Akt signaling, the main 
regulator of protein synthesis and degradation in the muscle16. In 
anabolic conditions, Akt phosphorylates FOXO3 and suppresses 
its transcriptional activity. FOXO3 inhibition in turn reduces 
the expression of the muscle-enriched members of the 
ubiquitin-proteasome system, atrogin-1 (FBXO32) and muscle 
RING finger 1 (MURF1)17, which promote muscle protein 
degradation. In addition, upon Akt activation, FOXO proteins may 
play a role in a negative feedback loop that inhibits Akt to main-
tain the cell homeostatic balance. In non-mammalian cells, FoxO 
orthologues inhibit the activity of the mechanistic target of 
rapamycin complex 1 (mTORC1)18,19, which drives muscle protein 
synthesis downstream of Akt16. In mammalian tissue, FOXO 
proteins reduce mTORC1 activity, thereby activating Akt20. 
FOXO proteins therefore may play an intricate role in balancing 
Akt and mTORC1 activities in response to changing metabolic 
conditions.
In mouse21–23 and human24 skeletal muscle, FOXO3 mRNA or 
total protein expression or both are upregulated under artificially 
induced catabolic conditions such as limb suspension or calorie 
restriction, suggesting that FOXO3 contributes to muscle wasting 
in these models. Recent rodent studies using immobilization mod-
els point toward myofiber type-specific regulation of FOXO323,25. 
However, a recent study showed no difference in FOXO3 
mRNA levels or in the cytoplasmic levels of the inactive phos-
phorylated FOXO3 protein in overweight young men subjected 
to energy restriction26, potentially because other factors per-
taining to insulin signaling may be at play. The complexity of 
FOXO protein regulation and the redundancy of FOXO alleles 
suggest that changes in gene and protein expression levels 
need to be interpreted with care, as they may not provide direct 
insights into the mechanistic processes at play.
Disease-induced catabolic states are also characterized by 
increased FOXO3 expression levels. Foxo3 mRNA levels were 
elevated in the late symptomatic stage of two mouse models 
of spinal muscular atrophy27. FOXO3 was also identified in a 
network-based analysis comparing serum proteomics in patients 
with Duchenne muscular dystrophy and age-matched controls28, 
suggesting potential for FOXO3 as a protein biomarker to 
monitor disease progression in conditions with severe skeletal 
muscle atrophy. Patients with chronic obstructive pulmonary 
disease displayed an increased ratio of phosphorylated FOXO3 
to total FOXO3 in their muscle when compared with healthy 
controls with or without sarcopenia29.
Whereas higher levels of FOXO3 are typically observed in 
pathological catabolic conditions, FOXO3 expression patterns 
are not upregulated in healthy old muscle. Sarcopenic mice 
display no change in nuclear or total FOXO3 protein expression 
despite reduced phosphorylation levels that might be indicative 
of higher FOXO3 activity30. We and others showed that FOXO3 
mRNA31,32 and FOXO3 nuclear protein levels decreased in 
old human skeletal muscle33 whereas total or phosphorylated 
FOXO3 protein expression did not change34. It is generally 
accepted that sarcopenia cannot be attributed to an upregulation 
of the proteolytic system or an induction of FOXO335. There-
fore, in aging muscle, FOXO3 may be similarly or even less 
active than in younger muscle or in models of artificially or 
disease-induced atrophy. Overall, these results confirm the idea 
that a series of upstream regulatory factors that inhibit FOXO3 
transcriptional activity, including peroxisome proliferator- 
activated receptor gamma coactivator-1-alpha (PGC-1α) 
and PI3K/Akt itself20, protect the muscle from aging-related 
atrophy36,37. In addition, the role of FOXO3 in the process of mus-
cle aging might rely on a fine balance between the regulation of 
protein turnover20 and other, protective anti-aging processes, such 
as the maintenance of the pool of skeletal muscle stem cells38, 
which is discussed below.
FOXO3 and the genetics of longevity
FOXO3 is among the few genes associated with human lon-
gevity that have been consistently replicated. Genetic vari-
ants of FoxO3 are associated with exceptional longevity in 
worms, flies, and mammals39. In humans, FOXO3 hosts about 
40 common, non-coding single-nucleotide polymorphisms 
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(SNPs) that have been consistently associated with longevity in 
Caucasian40–44 and Asian43,45,46 populations. FOXO3 gene and 
protein expression is associated with age-related phenotypes in 
multiple tissues47. For example, an age-dependent decrease in 
FOXO3 protein contributes to the loss of anti-inflammatory 
behaviorin macrophages of old mice48. Additionally, FOXO3-
deficient mice demonstrate signs of pronounced neural 
activation, apoptosis, and enteric neuronal loss, indicative 
of premature aging of the enteric nervous system48. FOXO3 
overexpression also facilitates autophagy, a process of degradation 
and recycling of cytoplasmic proteins and organelles that is 
essential for healthy aging in multiple tissues, including skeletal 
muscle49. However, the key role of FOXO3 in aging seems to be 
via the maintenance of stem cell homeostasis50, including in the 
brain51, blood52, and skeletal muscle38. Whether the modulation 
of molecular pathways involved in the age-dependent deteriora-
tion of stem cell function can reverse aging phenotypes remains 
controversial53. In skeletal muscle stem cells, termed “satellite 
cells”, FOXO3 enhances stem cell self-renewal via the activa-
tion of Notch signaling, maintaining an available pool of satel-
lite cells that have divided but retain their undifferentiated state38. 
In fact, FOXO proteins play a dual role, and in situations of cel-
lular damage, they can induce cell cycle arrest and senescence 
while independently repressing stemness signaling54. Yet, in 
humans, despite consistent associations between FOXO3 genetic 
variants and exceptional longevity40–46, a possible link between 
FOXO3 and healthy aging remains unclear. For example, 
the G allele of a longevity variant of FOXO3 was associated 
with a 10% reduction in all-cause mortality in a prospective 
cohort study of 3,584 older American men55. Moreover, in a 
cross-sectional study including more than 30,000 individuals, the 
G allele of another longevity variant of FOXO3 was associated 
with a decrease in concentration of circulating insulin-like 
growth factor-1 (IGF-1), a marker of insulin resistance and 
chronic disease56. Smaller-scale studies have yielded mixed 
results, albeit showing consistent trends. In the seminal study 
on FOXO3 and longevity (n = 615), carriers of FOXO3 longev-
ity variants had lower prevalence of coronary heart disease and 
insulin resistance43, echoing similar findings on hypertension 
in Japanese-American women57. In two recent studies on older 
Swedes (n = 1,520)58 and Danes (n = 1,088)59, carriers of the lon-
gevity alleles had better self-rated health even after accounting 
for cardiovascular disease incidence58, higher activity of daily 
living, and fewer bone fractures59. However, these latter findings 
did not survive adjustment for multiple testing59. Similarly, two 
functional longevity variants of FOXO3 failed to associate with 
mortality and age-related phenotypes in another sample of 643 
long-lived Danes60. A recent whole-genome sequencing study 
also found no differences in genotype distribution at FOXO3 
longevity variants between 511 healthy elderly and 686 
controls61. However, these small sample sizes suggest that these 
negative findings may partly reflect a lack of statistical power.
Two recent studies provide insight into how the longevity vari-
ants of FOXO3 may act at the molecular and cellular levels. 
In carriers of the G allele of a longevity variant of FOXO3, the 
FOXO3 gene was physically closer to its neighboring genes, and 
when exposed to stress, FOXO3 mRNA expression in lymphob-
lastoid cell lines derived from carriers increased more than in 
cell lines derived from non-carriers62. In line with those findings, 
another study showed that the same genetic variant has enhancer 
functions and that the G allele allows the creation of a novel 
transcription factor binding site, which induces FOXO3 mRNA 
expression in response to diverse stress stimuli63.
Collectively, these results suggest that FOXO3 genetic variants 
contribute to reaching old age, but there is a paucity of human 
studies that are sufficiently powered to demonstrate the role 
of FOXO3 in healthy aging60. One mechanism of action of 
the FOXO3 SNPs was only recently uncovered and involves a 
complex “interactome” whereby cellular stress causes FOXO3 to 
move close and physically interacts with no fewer than 46 flank-
ing genes on chromosome 664. Rather than just FOXO3, the strong 
association of FOXO3 with longevity might rely on the central 
position of FOXO3 in a chromatin domain containing essen-
tial genes involved in cell resilience, including autophagy, stress 
response, energy/nutrient sensing, cell proliferation, apoptosis, and 
stem cell maintenance62–64.
MicroRNA-mediated regulation of FoxO3
MiRNAs are regulatory, small non-coding RNAs. The physiological 
effect of most miRNAs is based on the post-transcriptional 
regulation of mRNA expression or the inhibition of protein 
translation65. Whereas correlations are often made between the 
expression levels of a specific miRNA and its predicted gene and 
protein targets, miRNA/mRNA direct regulatory relationships can 
be confirmed only via the means of luciferase reporter experiments 
in vitro. All of the miRNA/FOXO3 regulatory relationships 
discussed below were confirmed by luciferase validation.
MicroRNA regulation in autophagy and apoptosis
Increasing exogenous levels of miR-182 decreased FOXO3 mRNA 
and protein expression in C2C12 myotubes66 and FOXO3 protein 
levels in hair cells67. Downstream responses included an attenu-
ation of the mRNA levels of FOXO3 catabolic targets Fbxo32, 
autophagy-related protein 12 (Atg12), Cathepsin L (Ctsl), and 
microtubule-associated protein light chain 3 (Lc3) following 
atrophy-inducing dexamethasone treatment in C2C12 myotubes66 
as well as an attenuation of cisplatin-induced apoptosis and 
increase in cell survival in hair cells67. Similar to miR-182, elevated 
levels of miR-34a reduced FOXO3 protein levels and attenu-
ated lipopolysaccharide-induced autophagic activity in alveolar 
epithelial type II (AT-II) cells68. The opposite effects were 
observed when miR-34a levels were reduced. Other miRNA 
targets mediating apoptosis via FOXO3 include miR-223 and 
miR-15569–71. Apoptosis of peripheral blood macrophages is 
decreased in patients with tuberculosis, while isolated human 
macrophages transfected with mycobacterium tuberculosis (Mtb) 
strain H37Rv displayed an increase in endogenous miR-223 
levels. These results suggest an association between elevated 
levels of miR-223 and reduced apoptosis. In support of this, the 
overexpression of miR-223 in isolated human macrophages 
reduced apoptosis and suppressed FOXO3 protein levels. The 
miR-223 inhibitory effect on apoptosis was counteracted by 
FOXO3 overexpression71. Finally, expression levels of miR-155 
are increased in renal tissues of rats that have undergone ischemia/
reperfusion injury as well as in hypoxia/reoxygenation injury-
induced human kidney proximal tubules epithelial (HK2) cells70. 
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Overexpressing miR-155 in HK2 cells repressed FOXO3 mRNA 
and protein levels, increased caspase-1, interleukin-1 beta 
(IL-1β), and IL-18 mRNA and protein levels, and increased 
pyroptosis, a response that was attenuated by the suppression of 
miR-15570.
MicroRNA regulation in cell proliferation and growth
Prostate cancer (PC) tissue and primary prostate epithelial cell 
lines (PC cells) display increased expression levels of endogenous 
miR-59272 and miR-130773. Overexpression of these two 
miRNAs in PC cells inhibited FOXO3 protein levels and increased 
cell proliferation whereas suppressing their expression reversed 
these effects. Similarly, miR-592 levels were elevated, and 
FOXO3 mRNA and protein reduced, in colorectal cancer (CRC) 
tissues and cells74. In contrast, lentiviral-induced inhibition of 
miR-592 attenuated CRC cell proliferation and clonogenicity74. 
Overexpressing miR-551b, an miRNA that has elevated levels in 
ovarian cancer tissue, in isolated primary ovarian cancer (OVCa) 
cells increased proliferation, invasion, and chemoresistance of 
OVCa stem cells via the suppression of FOXO3 and TRIM31 
proteins75. In vivo, miR-551b inhibition increased the suscep-
tibility of OVCa cells to the chemotherapy drug cisplatin and 
prolonged the survival of host mice75. In contrast, miR-498 levels 
were decreased in ovarian cancer tissue. Overexpressing miR-
498 attenuated OVCa cell proliferation and was associated with a 
decrease in Cyclin D1 and increase in p27 expression, indicating 
that more cells remained in the G0/G1 phases of the cell cycle76. 
Of particular interest was the observation that the binding of 
miR-498 to FOXO3 3′-untranslated region increased its expression 
levels, an effect that is rare but not without precedent77,78. Finally, 
overexpression of miR-142-5p in chicken primary myoblasts79 
and miR-155-5p in human foreskin fibroblasts80 increased 
cell proliferation. This effect was mediated via a decrease in 
FOXO3 in both cell types. In the myoblasts, overexpressing 
miR-142-5p was associated with an increase in genes known to 
regulate growth such as IGF1R, IGF2R, IGF2BP2, MTH10, 
and PGK1. In the fibroblasts, overexpressing miR-155-5p inhib-
ited cyclin-dependent kinase inhibitor 1B (CDKN1B). These 
effects were reversed by the inhibition of endogenous levels 
of these two miRNAs.
This series of recent studies confirms that numerous miRNAs 
regulate FOXO3, often in a tissue-, cell-, or disease-specific 
manner. However, to date, the direct miRNA/FOXO3 relation-
ships have been assessed only under non-physiological and 
in vitro conditions. Although this fundamental work is essential 
and has significantly increased our understanding of the post- 
transcriptional regulation of FOXO3, research should now shift 
toward the in vivo regulation of FOXO3 targeting miRNAs 
in suitable animal models of human disease. Understanding 
how miRNAs regulate FOXO3 activity is of interest for many 
fields of biomedical research, as miRNAs potentially constitute 
novel and effective targets for human therapy81.
Mechanism protecting FOXO3 from microRNA regulation
Two mechanisms have been identified that protect FOXO3 
from being targeted by certain miRNAs. The Foxo3 pseudog-
ene (Foxo3P) and the Foxo3 circular RNA (circ-Foxo3) act as a 
“sponge” to bind miRNAs that normally would target FOXO3. 
Several miRNAs, including miR-22, miR-136, miR-138, miR-149, 
miR-433, miR-762, miR-3614-5p, and miR3622b-5p, all interact 
with FOXO382 but do not cause transcript degradation. Competi-
tion assays and luciferase reporter assays revealed that Foxo3P 
and circ-Foxo3 can compete with Foxo3 for binding to these 
miRNAs. This competitive inhibition results in an increase 
in FOXO3 translation. Foxo3P and circ-Foxo3 are endog-
enously expressed in non-cancerous lines such as BEAS2B, 
HaCaT, and MCF-10A. When these cells are transfected with 
Foxo3, Foxo3P, or circ-Foxo3 and exposed to hydrogen per-
oxide (H2O2), cell survival decreases. Additionally, nude mice 
injected with MDA-MB-231 cells overexpressing Foxo3, Foxo3P, 
or circ-Foxo3 have small tumor growth, demonstrating that 
Foxo3P or circ-Foxo3 has functional consequences similar to 
those of Foxo3.
Conclusions
FOXO3 has versatile functions in human health and disease, 
and recent research offers new insights into the molecular 
mechanisms underlying the role and regulation of this essential 
transcription factor. Over the last 3 years, an important part of 
FOXO3 research has focused on longevity studies combining 
population epidemiology and molecular investigations, and the 
aim has been to pinpoint the mechanisms that underlie the role of 
FOXO3 in longevity. Simultaneously, numerous new findings high-
light the important role of miRNAs in the regulation of FOXO3 
and their implication in the regulation of cell cycle-related 
processes. Overall, despite a strong association of FOXO3 with 
aging phenotypes, its role in healthy aging remains unclear, 
especially in skeletal muscle. This may constitute an exciting 
focus for research in the future.
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